Literature DB >> 30626561

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.

Hamid Sayar1, Larry D Cripe2, Antoine N Saliba3, Mohammad Abu Zaid2, Heiko Konig2, H Scott Boswell4.   

Abstract

Entities:  

Keywords:  AML; Acute myeloid leukemia; Bortezomib; Sorafenib; Vorinostat

Mesh：

Substances：

Year:  2018        PMID： 30626561     DOI： 10.1016/j.leukres.2018.12.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


× No keyword cloud information.
  4 in total

Review 1.  FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.

Authors:  Baku Acharya; Debasmita Saha; Daniel Armstrong; Naga Rajiv Lakkaniga; Brendan Frett
Journal:  RSC Med Chem       Date:  2022-05-23

Review 2.  HDAC Inhibitors in Acute Myeloid Leukemia.

Authors:  Edurne San José-Enériz; Naroa Gimenez-Camino; Xabier Agirre; Felipe Prosper
Journal:  Cancers (Basel)       Date:  2019-11-14       Impact factor: 6.639

Review 3.  Role of Biomarkers in FLT3 AML.

Authors:  Jiao Wei; Ai-Min Hui
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

4.  Functional Drug Screening of Small Molecule Inhibitors of Epigenetic Modifiers in Refractory AML Patients.

Authors:  Jessica L Dennison; Hassan Al-Ali; Claude-Henry Volmar; Shaun Brothers; Justin Watts; Claes Wahlestedt; Ines Lohse
Journal:  Cancers (Basel)       Date:  2022-08-24       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.